Ac Immune News Today : Breaking News, Live Updates & Top Stories | Vimarsana

We can readily understand why investors are attracted to unprofitable companies. For example, although...

AC Immune Announces Upcoming Presentations at AD/PD™ 2024 Multiple presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024)Andrea Pfeifer, Ph.D., CEO to lead AC Immune-sponsored symposium on alpha-synuclein pathologies Lausanne, Switzerland, February 22, 2024 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upcoming presentations highlighting its preci

AC Immune SA (NASDAQ:ACIU – Get Free Report) was the recipient of a large drop in short interest during the month of January. As of January 31st, there was short interest totalling 480,600 shares, a drop of 14.1% from the January 15th total of 559,300 shares. Based on an average daily trading volume, of 127,500 […]

Shares of AC Immune SA (NASDAQ:ACIU – Get Free Report) traded up 13.8% during trading on Monday . The company traded as high as $4.92 and last traded at $4.87. 277,917 shares were traded during trading, an increase of 51% from the average session volume of 184,616 shares. The stock had previously closed at $4.28. […]

AC Immune’s Targeted Anti-pTau Active Immunotherapy for Alzheimer’s Disease Advances into Phase 2b Trial Potentially registration-enabling Phase 2b study (ReTain) will evaluate the effect of ACI-35.030 on cognition and Tau pathology in approximately 500 participants with preclinical Alzheimer’s disease (AD)Anti-pTau active immunotherapy being designed to potentially prevent or reduce cognitive decline could address need of over 315 million people globally1 with preclinical ADAC Immune to receive